Loading organizations...
Loading organizations...
NodThera is a technology company.
NodThera is a biotechnology company developing novel treatments for chronic inflammatory diseases. It designs and advances a new class of potent, highly selective NLRP3 inflammasome inhibitors. This technical approach targets the underlying biological mechanisms of inflammation at its source, addressing conditions driven by dysregulated innate immune responses.
Founded in 2016, NodThera emerged from a scientific insight into the critical role of the NLRP3 inflammasome in chronic inflammation. A team of experienced scientists and industry leaders established the company to translate this understanding into therapeutic solutions. Their collective expertise underpinned the commitment to precisely modulating the NLRP3 pathway for patient benefit.
NodThera focuses on developing therapies for patients suffering from various chronic inflammatory diseases where current treatments are inadequate. The company's long-term vision centers on delivering innovative medicines that significantly improve the lives of individuals impacted by these conditions by effectively controlling inflammation. They aim to make a substantial impact in areas of high unmet medical need.
NodThera has raised $95.0M across 2 funding rounds.
NodThera has raised $95.0M in total across 2 funding rounds.
NodThera has raised $95.0M in total across 2 funding rounds.
NodThera's investors include 5AM Ventures, Dave Maki, ARCH Venture Partners, Atlas Venture, Cathay Innovation, Eight Roads Ventures, Firstminute Capital, Forbion, F-Prime Capital Partners, Frst, Plug & Play Ventures, Polaris Partners.
NodThera is a clinical-stage biotechnology company developing oral, small-molecule NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases at their source, targeting conditions like cardiovascular disease, obesity, osteoarthritis, Parkinson's disease, and neuroinflammation.[1][2][3] Its lead candidates, including NT-0796 and NT-0249, demonstrate brain penetration, potent anti-inflammatory effects, and potential best-in-class profiles, serving patients with limited treatment options by addressing upstream inflammation drivers.[1][3][6] The company shows strong growth momentum, with positive Phase Ib/IIa data in Parkinson's (reversing neuroinflammation biomarkers), a Phase 2 obesity study initiating in Q2 2025, and backing from top investors like 5AM Ventures, Novo Holdings, and Sanofi Ventures.[1][3]
Headquartered in Boston, MA, with operations in Cambridge, UK, and Seattle, WA, NodThera combines pharmaceutical neuroscience, precision chemistry, and NLRP3 expertise to advance its pipeline, including NT-0796 (Phase 1/2 in inflammation and Parkinson's), NT-0249 (Phase 1), and preclinical assets.[2][3][6]
NodThera was founded in 2016 in Little Chesterford, United Kingdom, at Chesterford Research Park, emerging from scientific evidence positioning the NLRP3 inflammasome as a key driver of chronic inflammation in diseases affecting the body and brain.[1][2] The idea stemmed from biotech innovators recognizing NLRP3's role as an upstream catalyst, enabling targeted inhibition to deliver viable medicines where options were inadequate.[2]
Early traction built on the team's expertise: leaders like President and Chief Scientific Officer Alan Watt, Chief Medical Officer Dr. Jyothis George (ex-Amgen and Novo Nordisk, joined 2025), and board members including Dr. Don Nicholson and Dr. Scott Morrison (serial entrepreneur with MIT PhD).[3][4] Pivotal moments include advancing brain-penetrant candidates and securing investor support, relocating headquarters to Boston while expanding globally.[1][3]
NodThera's edge lies in its focus on NLRP3 inflammasome inhibition, offering a paradigm shift by targeting inflammation's source with differentiated, oral small molecules.[1][2]
NodThera rides the NLRP3 inhibition wave in biotech, fueled by evidence linking inflammasome dysregulation to chronic diseases amid rising neuroinflammation and cardiometabolic burdens.[2][3] Timing aligns with GLP-1RA dominance in obesity/weight management, where NodThera's combo approach (e.g., NT-0796) promises sustained, healthier outcomes by correcting brain/body pathways.[1]
Market forces favor it: aging populations drive demand for Parkinson's/neurodegenerative therapies; inflammation's role in comorbidities amplifies opportunities.[3][6] NodThera influences the ecosystem by validating NLRP3 as a multi-indication target, inspiring competitors and attracting investment in precision inflammation biotech.[1][2]
NodThera is poised for inflection with Phase 2 obesity data in 2025 and Parkinson's readouts, potentially unlocking blockbuster indications via NLRP3's versatility.[1][3] Trends like AI-driven drug discovery and combo therapies with GLP-1s will accelerate its pipeline, while brain-penetrant innovations position it against neuroinflammation rivals.[6]
Influence may evolve through partnerships or acquisitions, given strong investor backing and patent estate, cementing NodThera as a leader in source-targeted inflammation treatments—transforming patient outcomes from symptom management to disease halt.[2][4]
NodThera has raised $95.0M across 2 funding rounds. Most recently, it raised $55.0M Series B in June 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2020 | $55.0M Series B | 5AM Ventures, Dave Maki, ARCH Venture Partners, Atlas Venture, Cathay Innovation, Eight Roads Ventures, Firstminute Capital, Forbion, F-Prime Capital Partners, Frst, Plug & Play Ventures, Polaris Partners, Soffinova Partners, Third Kind Ventures | |
| Jun 1, 2018 | $40.0M Series A | 5AM Ventures, Soffinova Partners | Dave Maki, ARCH Venture Partners, Atlas Venture, Cathay Innovation, Eight Roads Ventures, Firstminute Capital, F-Prime Capital Partners, Frst, Plug & Play Ventures, Polaris Partners, Third Kind Ventures, Elizabeth Roper, F-Prime Capital |